Similar articles

• [Dyslipidemias in renal diseases: pathogenesis and treatment].

  Cuevas A, Maíz A, Arteaga A. Cuevas A, et al. Rev Med Chil. 1998 Mar;126(3):315-21. Rev Med Chil. 1998. PMID: 9674303 Review. Spanish.
• K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease.

  Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. Am J Kidney Dis. 2003 Apr;41(4 Suppl 3):I-IV, S1-91. Am J Kidney Dis. 2003. PMID: 12671933 No abstract available.
• De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications.

  Lentine KL, Schnitzler MA, Abbott KC, Li L, Burroughs TE, Irish W, Brennan DC. Lentine KL, et al. Am J Kidney Dis. 2005 Oct;46(4):720-33. doi: 10.1053/j.ajkd.2005.06.019. Am J Kidney Dis. 2005. PMID: 16183428
• The impact of living donor kidney transplantation on markers of cardiovascular risk in chronic kidney disease patients.

  Bignelli AT, Barberato SH, Aveles P, Abensur H, Pecoits-Filho R. Bignelli AT, et al. Blood Purif. 2007;25(3):233-41. doi: 10.1159/000101028. Epub 2007 Mar 23. Blood Purif. 2007. PMID: 17377377
• Atherosclerosis and lipid disorders after renal transplantation.

  Drüeke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Drüeke TB, et al. Kidney Int Suppl. 1991 Apr;31:S24-8. Kidney Int Suppl. 1991. PMID: 2046266 Review. No abstract available.